David Nierengarten

Following the SOLO-2 trial results surpassing expectations, Wedbush’s David Nierengarten stated that the data demonstrated “similar top-line efficacy for Lynparza as that achieved by niraparib in the NOVA study.” The analyst reiterated an Outperform rating on TESARO Inc (NASDAQ:...

During its fourth-quarter 2016 earnings call, Juno Therapeutics Inc (NASDAQ: JUNO) announced it would discontinue development of JCAR015. This development was expected, since JCAR017 is “demonstrating potential for a best-in-class efficacy and safety profile for CD-19 directed CAR-T therapy,...

Wedbush’s David Nierengarten expects “several major data readouts” ahead in 2017 to act as catalysts for bluebird bio Inc (NASDAQ: BLUE). The analyst reiterated an Outperform rating on the company, with a price target of $95. Data As Catalyst “Early data from registration-...

Wedbush analyst David Nierengarten maintains his Outperform rating and $95 target price on bluebird bio Inc (NASDAQ: BLUE), which announced positive results from its early-stage cancer study. Cambridge, Massachusetts-based bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed...

Wedbush Securities reiterated its Outperform rating and $117 target price on bluebird bio Inc (NASDAQ: BLUE) after the company’s R&D Day highlighted improvements to gene therapy platform and favorable regulatory response. The company’s LentiGlobin BB305 product candidate is...

Wedbush Securities reiterated its Outperform rating and raised its price target on TESARO Inc (NASDAQ: TSRO) shares to $139 from $107 as it "sees the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market." Waltham,...

Wedbush has started coverage of Audentes Therapeutics Inc (NASDAQ: BOLD) with an Outperform rating and $20 price target, citing the stock as "a compelling opportunity." Audentes' AAV-based gene therapy programs are targeted at Pompe disease, X-linked multiple myopath and Crigler-Najjar, a rare...

Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...